November 10, 2026 · Part 2 · 19,332 words · 7 speakers · 92 segments
Let's begin again. Who would like to go first?
Great. Thank you. Great. Good afternoon. My name is Jonathan Taien. I am the president and CEO of the Associated Medical Schools of New York and the New York State Academic Dental Centers. And I want to thank Chairs Starpey, Conrad, and Buttenshawn for inviting me to give testimony and to the other members of the Assembly. I wanted to first start with a little bit of background on the state of biomedical research in New York. As a reminder, New York State is the second leading recipient of funding from the National Institutes of Health, about $3.5 to $3.6 billion in the most recent years. And that supports research across our now 18 medical schools, supports directly 17,000 jobs that are medical schools. And of course, there's a major economic driver, both statewide, but also regionally. And our medical schools are both upstate, downstate Long Island, and where they are situated are major sort of regional hubs for both, of course, medical care, but also for developing new treatments and cures and driving the life sciences sector. So the last couple of years, though, have been particularly challenging from a competition standpoint. I really do want to focus my remarks this afternoon on our scientific workforce because they are facing some unprecedented challenges. The last two years have really seen a significant spike in competition, not just within the U.S., but globally for scientists. And so in California, we've seen them invest billions of dollars. In fact, over the last 20 years now, they've committed $8.5 billion to the California Institute for Regenerative Medicine, which focuses on stem cell research. And in fact, I think it was just yesterday that the LA Times reported that Proposition 38 in California passed, which commits another eight and a half billion dollars to a brand new immunology institute. And in fact, in 2028, voters in California will be voting on a $7.5 billion initiative to establish essentially a state-level NIH to fund research. In Texas, they have committed to date $6 billion to their cancer research program. Last year, they committed another $3 billion to a brand new dementia research program. And Massachusetts, they have a billion and a half that they've committed to their Life Sciences Institute. And Governor Healy last year committed another million to support scientists who are losing funding from the NIH So I say all of this to sort of paint a picture of what our scientists here in New York are facing which is that NIH funding is becoming more difficult to come by. So in the last couple of years, we've actually seen, despite a level funding, so funding has remained steady at about three and a half, 3.55 billion dollars from 2024 to 25 and now 26. But because of some policy changes within NIH and how they're actually dispersing funds, we've seen a reduction of more than 550 awards just to New York State. That means 550 scientists who no longer have funding from the National Institutes of Health. But in particular, we're hearing from our early career scientists that they are unsure whether they can continue their work in New York and, in fact, within the U.S., because there's not a clear sense of what NIH funding is going to be. And NIH really is the primary source for funding biomedical research. And sort of absent that certainty, we hear from a lot of our PhD students and postdocs and early career scientists that they may have to consider going overseas. And in fact, we've seen scientists who have accepted positions to open their labs from China. China has invested billions of dollars in recruitment and Canada as well. And so we really think that focusing on workforce is essential. Assemblyman Sturpey mentioned the New York First program earlier. That has been a critical workforce initiative, and I would urge that we fund that program robustly and think about other ways that we can support our scientific workforce. Thank you.
There we go. There we go.
Chair Sturpe, Buttonshon, Conrad, members Cashman and Stern, thank you very much for having us today. My name is Wynne Thurlow. I'm the Executive Director of Life Sciences New York. We are a statewide association of life sciences companies and universities with a mission to grow the life sciences as it relates to human health here in New York. When I talk about the life sciences, what we're really talking about are the companies and individuals who are researching, innovating, and manufacturing medical devices, pharmaceuticals, diagnostic tools. Our members in the life sciences range from individual researchers and startups up through large multinational companies here in New York, like Siemens Healthineers, Regeneron, Baxter, and others. And we also have in our membership the whole range of companies that support the life sciences, whether they are research organizations, contract manufacturers, consultants in those. And I want to reiterate much of what I heard from Jonathan and also say that as we look at particularly the workforce development issues for those of us in the life sciences the workforce needs run the gamut of all employment in New York from high school graduates through post graduates And one of the things that I have been most encouraged by particularly recently is the state appreciation of the breadth of those workforce needs and the development and implementation of programs that meet many of those needs, whether they are manufacturing needs or whether they are attracting world-class talent. We need to recognize that New York is a leader in the life sciences. And at the same time, it is an incredibly competitive environment. And we are at risk of losing our competitive advantages if we don't continue to make targeted investments across the life sciences needs. One of the things that I will tell you that I think is particularly encouraging to me is as I look at the governor's bolstering biotech initiative that identifies some significant areas of investment that leverage existing strengths that we have in New York. We need to expand access to clinical trials. Frankly, we live in the most diverse state, in the most diverse country in the world. we have an ability to access patients and community groups that are not currently being reached. Expanding clinical trials is absolutely critical to the development of medical products. Workforce development, as we've talked about, is a critical piece in this puzzle, as is the ability to connect early-stage companies to investment capital. As much as New York is a world-class home for investors, the reality is investment capital in the life sciences is a particularly challenging issue. Developing medical devices and pharmaceuticals typically takes anywhere from 8 to 10 years from ideation through commercial readiness. There are a lot of meals to eat over the course of those 10 years, and that makes it a particularly challenging place to find investors who are willing to support those early stage companies. This is a problem that is particularly acute across the upstate region. And as we look at the success that we've had in developing the biomed ecosystems across the state, it is important that we continue to focus on those investments that are having measurable quality outputs. Thank you very much.
All right. You talked about, you know, the other states, California, Texas, Massachusetts, and we're talking really big numbers, eight and a half billion dollars. Over how many years is that funding?
So typically these initiatives are over 10 years. And in the case of California, they're typically bond funded initiatives. So, you know, the structure there is a little bit different. Texas as well, they started their cancer program with bond funding. But again, the time horizon is generally over 10 years. I think one of the benefits there is, again, having certain funding, having stability of funding and predictability. And that's really been one of the challenges that we seen with significant changes in federal policy is that certainty is no longer there And so as Wynne said you know when you got a 10 or more time horizon for developing you know, treatment from the discovery phase to being able to bring it to marketplace, you need predictable funding. And absent that, we really will see folks have to reconsider where they pursue their efforts.
I mean, New York, you know, has been a leader for a long time in this area. They have a lot of infrastructure built up. Does that give New York any advantage when we're looking at recruiting someone to come to New York? You know, you end up living near New York City and go to Broadway. You can do a whole bunch of different things in addition to going to work every day. But do you think that is an advantage so that if we increased our funding to a certain level, we would still win a lot of these opportunities? Yeah.
So maybe I'll start. So from the academic perspective, New York is one of the epicenters of the universe for biomedical research. We have been one of the leaders since the NIH was formed in the aftermath of World War II. And that has allowed us to build an enormous amount of infrastructure to support all of this work. We have some of the very best scientists in the world across a very wide range of disciplines. And people want to work here. We hear this from our postdocs. We hear this from early career scientists. They want to do their work in New York, but they're not sure they can right now. So I think for us, we're not running to play. We're not playing catch up. We don't have to build out this infrastructure. We have it in place. the danger is losing the human capital that then makes that infrastructure useless. And so I think that that really is the challenge. But I think the bright side here is that we have all of the tools in place. What I think we need is that stable partnership with state government that doesn't replace, doesn't even attempt to replace federal funding, but complements it and helps us weather any policy changes that might come in future. You know, I'm mindful, Rainier Brentgens, who's one of the leaders at Roswell Park Comprehensive Cancer Center in Buffalo, has a great line that I will steal from him when he talks about workforce recruitment. He says the two largest problems or two largest challenges in recruiting workforce to Buffalo, New York, is one, getting people to come to Buffalo, two, getting people to leave Buffalo. And I think that is generally true across the state. And what he really is getting at is an underlying truth, which is to say we have an incredible richness of both facilities, talent, and opportunities. This is a space, to your point, Assemblyman Sturvey, that the infrastructure really matters, right? To be able to offer incoming talent the facilities that they need to be able to lead what they're doing is an incredible draw. The reality, frankly, often is that when you are trying to recruit high quality talent, it isn't necessarily the institution, but it's the opportunities in the You look at the development in the microchip space, I think that's a huge benefit for all of us across the state because it enriches the larger workforce. And so we are better able to recruit potential high-talent folks who are coming almost invariably with spouses, partners, or others who work in adjacent fields. And we need to be able to provide them opportunities. And that's one space where I think the infrastructure investments are really paying dividends. Do you think, you know, because of this better than most infrastructure advantage we have, have any, I mean, companies stepped up a little bit more trying to keep things here in New York as the cuts took place? you would think there are you know companies that know this particular research has been going on here and there's not just the infrastructure with people working on stuff and they don't want it to all of a sudden move someplace else where they don't have as good a handle on it it's so they have they invested or promised they would invest more money let me let me say this the short answer to your question is yes. But here's what I would also say to you. As you look at the level of federal funding for basic science research, it is true that it is probably more endangered today than it has been at any time in the past. The reality, however, is that as a percentage of available funding, it has been falling for several decades at this point. And we really need to focus on building durable, sustainable relationships between industry and academia to both fill those gaps and supplement what we're looking at in terms of other funding opportunities. Industry funding for research follows available existing funding that's out there. So we need to recognize that we will attract industry funding when we have available funding for those companies to piggyback on. That's what advances the development of products. Now, I would also say to you that we have spent a lot of time in the public realm talking about the impacts that cuts will have on our academic institutions. I think one thing that we have not spent enough time thinking about is the impact on the new product pipeline, right? If we're having less research and innovation coming out of our universities, we're going to have fewer pharmaceuticals, fewer medical devices, fewer diagnostics. And that's the space, to your point, that industry needs to recognize it's a shared responsibility. And we have an opportunity with some targeted investments to find those opportunities. If I could briefly add to that,
So agree with everything that Wynne said. I think, and currently, you know, our medical schools have many, many partnerships with and collaborations with the private sector on specific research. I think one of the things that we need to be mindful of, though, is, and I want to underscore this, that the basic science research that really is the purview of academia is essential in this. If we are only focused on the things that have immediate potential, we lose opportunities. I think the biggest and the greatest example of this is the biggest blockbuster drug we seen in recent years which are GLP drugs That was not a pharmaceutical company looking for a new weight loss drug In fact, this was a basic science researcher studying helomonsters. Absolutely no connection whatsoever to the thing that ended up becoming, you know, again, the largest blockbuster we've seen in recent years.
I mean, anytime when you're in a situation of scarcity, you have to prioritize things. So, I mean, I know that in this past budget, we had the $65 million that the governor put in. I tried to get another $100 million because we thought maybe the money the governor had put in was more for the end part of research. and I was looking at the front part where you got postdocs and stuff making a decision where they're going to live and having them you know dig in and live here in New York. Do you think as we go into the next session we should be focusing more on that part of it to be very specific or just we need more money all the way around just trying to figure out the approach I
This page shows part of the transcript. The full transcript is available on request.